Table 3.
Gene expression associates with clinical outcomes.
| Gene expression | P value | Association with clinical outcome | Pathways involved with IBD |
|---|---|---|---|
| ↑ IRGM | P = 0.001 | Medical treatment response to aminosalicylates (5-ASAs) | Autophagy |
| ↑ FOXO4 | P = 0.05 | Histological remission | Immune response |
| ↑ CTLA4 | P = 0.05 | Histological activity index score | |
| ↓ SLC26A3 | P = 0.001 | Clinical course: the course of the same initial activity and prolonged remission | Solute transport |
| ↑ SLC39A4 | P = 0.0007 | Evolution: tendency to years of evolution of between 10 and 15 years | |
| ↑ SOD2 | P = 0.00004 | Severe histological activity | Oxidative stress |
| ↑ TDO2 | P = 0.06 | Clinical course: characterized by the presence of initial activity and then prolonged remission more than 5 years | |
| ↑ ALDOB | P = 0.005 | Evolution: early age at diagnosis of less than 40 years | Carbohydrate metabolism |
| ↑ ALDOB | P = 0.005 | Clinical course: prolonged benign clinical course characterized by the presence of higher initial activity and remission at 5 years |